Non-peptide

Ligandrol recomp stacks (SARM multi-agent culture)

Also known as

SARM stacks · RAD+LGD culture threads · LGD recomp stacks · Ligandrol stack · LGD-4033 stacks · LGD + RAD stack · LGD + ostarine stack · LGD + Cardarine stack · LGD + MK-677 stack · SARM stack culture (multi-agent discussion unit) · multi-SARM recomp cycle · kitchen-sink SARM blend

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A discussion category for oral LGD-4033-centered combinations aimed at getting leaner while retaining or gaining muscle, rather than a single molecule.
Different partners	RAD-140 and ostarine are SARMs; Cardarine is a different metabolic drug and MK-677 a growth-hormone secretagogue. Fixed blends can hide each component's amount.

Notes

What it is: A discussion unit, not a single molecule — multi-compound oral “recomp” stacks centered on LGD-4033 (Ligandrol / VK5211) plus one or more partners from gray-market SARM/PED culture. [community]

Hold muscle while losing fat. Recomp means getting leaner while retaining or gaining muscle. Posters assign LGD fullness and strength, RAD a drier look, ostarine muscle retention or joint comfort, and Cardarine easier cardio. These are community expectations, not demonstrated stack rankings. Last Cycle - Stacking LGD/Osta/Cardarine (Community discussion · Accessed 2026-09-30)

LGD is the anchor; the partners change. LGD-4033, also called Ligandrol, is an oral SARM: a drug that acts at androgen receptors. RAD-140, ostarine and S-4 are other SARMs. Cardarine is a different metabolic drug; MK-677 stimulates growth-hormone release. Calling them all SARMs hides different effects and risks.

Oral liquids, capsules and fixed blends. These discussions concern whole-body exposure, not a local repair peptide. Separate bottles and premixed products appear; a blend prevents adjusting one ingredient independently. A label’s combined milligrams do not identify each component’s amount.

Source context — Last Cycle - Stacking LGD/Osta/Cardarine: Plan revised in discussion, not a completed cycle. Oral context from original; specific product form not supplied.

What people notice

Training and appearance	Accounts describe strength, fullness, less soreness or better definition, but also mostly water-weight gain and some fat gain. One user found less benefit and more suppression than LGD alone.
Hunger and bloat	MK-677 hunger can undermine a calorie deficit. Users disagree about water retention, and a fuller look does not establish new muscle or fat loss.
Adverse changes during use	Mood, libido and energy can worsen. One testosterone/LGD/RAD account reported erectile dysfunction around weeks three to four.

Notes

Less soreness, mostly water, or no extra benefit. LGD/ostarine reports include less soreness and better definition alongside mostly water-weight gain and some fat gain. A different user said the combination produced fewer gains than LGD alone and more suppression. Joint comfort is not proof of tissue healing. LGD + Ostarine stack (Community discussion · Accessed 2026-09-30) · Stacking LGD-4033 with Ostarine. Useless stack? (Community discussion · Accessed 2026-09-30)

Feeling good can coexist with concerning values. A July 2026 LGD/MK-677 log reported strength gains but testosterone falling from 576 to 112 ng/dL and HDL from 49 to 28 mg/dL. These are self-reported numbers, not independently verified labs; mood and swelling also changed. CYCLE REVIEW: 10mg LGD + 7.5mg MK677 (8 weeks) (Personal report · Accessed 2026-09-30)

More training capacity, sometimes more appetite. MK-677 is added for sleep, hunger and recovery feel. Hunger can help a bulk but undermine a calorie deficit. A better workout or fuller appearance does not establish fat loss or new muscle. LGD/MK677 on a cut (Community discussion · Accessed 2026-09-30)

Hunger and bloat can derail the cut. Cutting-thread replies disagree about how much water LGD brings. The original poster said MK-677 had not bloated them; others described intense hunger. Cardarine’s proposed fat-burning role was disputed even within that thread. LGD/MK677 on a cut (Community discussion · Accessed 2026-09-30)

Symptoms during use: Some dual-SARM accounts describe lethargy or flat libido. Those symptoms do not measure suppression or show that one hormone effect has overtaken an anabolic effect. [anecdote]

Sexual side effects can emerge mid-cycle. Another commenter reported erectile dysfunction three to four weeks into testosterone, LGD and RAD co-use. Their explanation involving lipids was speculation. Their subsequent medication use does not establish a treatment for other users. LGD + Ostarine stack (Community discussion · Accessed 2026-09-30)

Source context — LGD + Ostarine stack: Distinct authors and stacks; self-reported amounts with incomplete frequency/form. Collapsed More replies not inspected. No verified product analysis or causal diagnosis.

Source context — Stacking LGD-4033 with Ostarine. Useless stack?: Theory is not an outcome; S-4/MK account is not LGD/ostarine evidence. No source confirms tenfold potency or S-4 half-life claimed by a commenter.

Source context — CYCLE REVIEW: 10mg LGD + 7.5mg MK677 (8 weeks): Daily frequency and product form not stated in inspected body; photos/lab images not validated. Multiple supports and clomiphene bridge confound effects. Expected retained muscle and hormone recovery remain unmeasured.

Source context — LGD/MK677 on a cut: OP had not completed proposed stack; no blend quantities. Commenter's acute hunger is MK-specific. M-Sten adjunct plan not presented as a stack recommendation.

Doses people talk about

LGD component	Older oral charts separate 2.5–5, 5–10 and 10–15+ mg/day of LGD itself. These are reported bands, not safety tiers.
Partner components	Separate charts list RAD 5–30 mg/day, ostarine 10–25 mg/day sometimes 30, Cardarine 10–20 mg/day and MK-677 10–25 mg/day. Each amount belongs to that partner.
Actual dual report	One LGD/ostarine user reported 10 mg of each every morning. Another ten-week account changed from 10/15 mg to 15/22.5 mg; daily frequency was not explicit there.
Blend concentration	One label listed LGD 20, ostarine 25 and MK-677 20 mg per mL, totaling 65 mg/mL. That concentration does not state the daily swallowed amount.

Notes

LGD component: 2.5–5, 5–10, or 10–15+ mg/day. These separate oral bands occur in the older community record, not safety tiers. Partner charts list RAD 5–10, 10–20 or 20–30 mg/day; ostarine 10–25 mg/day, sometimes 30; Cardarine 10–20; MK-677 10–25. Each amount belongs to that drug, not the entire stack.

Actual LGD/ostarine reports differ. One user reported 10 mg of each every morning. Another described LGD 10 mg with ostarine 15 mg for four weeks, then 15 mg with 22.5 mg for six weeks; daily frequency is implicit in the cycle account, not explicitly stated. LGD + Ostarine stack (Community discussion · Accessed 2026-09-30)

Liquid blend: 20, 25 and 20 mg per mL. A T Nation poster described LGD, ostarine and MK-677 in that order, totaling 65 mg/mL. That is labeled concentration, not the amount swallowed each day; the thread does not establish blend contents or a completed stack result. SARMS 3D Stack Help? (Community discussion · Accessed 2026-09-30)

Source context — SARMS 3D Stack Help?: Label concentration and purchase question, not analytic confirmation or completed stack log. Seller's unsupported 80% side-effect rate and safety/efficacy assurances rejected.

Half-life, onset & duration

Felt onset	Older accounts put fullness in days 1–7 and training changes in weeks 1–2. A separate 12.5 mg MK-677 report described intense hunger in about two hours.
Felt duration	No reliable single-dose benefit window is established. Repeated-use logs and feeling well after stopping do not establish retained muscle or hormone recovery.
LGD half-life	24–36 hours is derived from a low-dose LGD-only human trial and repeated online. There is no single half-life for the whole stack.

Notes

Early feelings and later physique changes differ. Older accounts place fullness in days 1–7 and training changes in weeks 1–2. An LGD/ostarine user described malaise for the first three days; another reported little soreness nearly a month in. These are different endpoints, not one onset clock. LGD + Ostarine stack (Community discussion · Accessed 2026-09-30)

An adjunct can be felt much sooner. In a cutting discussion, a commenter described intense hunger roughly two hours after 12.5 mg MK-677. That was an MK response, not onset of the planned LGD blend’s recomp effect. LGD/MK677 on a cut (Community discussion · Accessed 2026-09-30)

Single-dose benefit duration is unknown. Daily-use logs describe weeks of training and appearance changes. They do not show how long one dose improves performance. A 2026 LGD/MK-677 author expected weight loss after stopping but had not measured retained muscle at that point. CYCLE REVIEW: 10mg LGD + 7.5mg MK677 (8 weeks) (Personal report · Accessed 2026-09-30)

Feeling recovered does not establish recovery. The same author later reported good energy and strength 23 days into post-cycle treatment, while saying repeat testosterone testing had not happened. Persistent benefit, normal hormones and drug clearance are separate questions. CYCLE REVIEW: 10mg LGD + 7.5mg MK677 (8 weeks) (Personal report · Accessed 2026-09-30)

LGD’s repeated figure is 24–36 hours. A Reddit timing debate explicitly links this number to the low-dose LGD-only human trial through More Plates More Dates. It is trial-derived information repeated by users, not a community measurement of a stack. Taking LGD 1 day on 1 day off because of 24+ hour half life? (Secondhand community claim · Accessed 2026-09-30)

There is no single stack half-life. Partners have separate kinetics. Older summaries repeat about 24 hours for ostarine and describe once-daily or split Cardarine and nighttime MK-677. Timing habits are not measured clearance. Feeling residual effects for weeks cannot establish a longer drug half-life. Taking LGD 1 day on 1 day off because of 24+ hour half life? (Secondhand community claim · Accessed 2026-09-30)

Source context — Taking LGD 1 day on 1 day off because of 24+ hour half life?: No independent community PK measurement. Subjective residual effects and accumulation do not demonstrate an altered half-life or endorse alternate-day dosing.

Cycles people discuss

On-course charts	Older patterns include 6–8 weeks, with separate 4–6, 8–10 and 8–12-week plans. One newer account described three months on and five months off.
Post-cycle treatment	Charts discuss tamoxifen 10–20 mg/day for about four weeks or clomiphene-based 3–6-week blocks. Start timing varies from next day to 1–2 weeks later; no recovery schedule is validated.
Time off	Equal-or-longer time off, sometimes plus post-cycle treatment time, is a forum rule of thumb. Feeling recovered does not establish normal hormones.

Notes

Six to eight weeks is an older chart pattern. The record also contains 4–6, 8–10 and 8–12-week plans. A newer pill-stack author reported three months on and five months off; that is one account, not a safe alternative calendar. Rad140+MK677+LGD+OSTARINE+Tudca (Personal report · Accessed 2026-09-30)

Post-cycle treatment is contested. Older charts discuss tamoxifen 10–20 mg/day for about four weeks, or clomiphene-based blocks of 3–6 weeks. Starts range from the next day to days or 1–2 weeks later; minority on-cycle SERM use also appears. None establishes a validated recovery schedule.

Break rules do not prove readiness. Equal-or-longer time off, sometimes plus treatment time, is a forum heuristic. Solo-first versus stack-first and adding a testosterone base remain disagreements; extra drugs complicate attribution and recovery.

Source context — Rad140+MK677+LGD+OSTARINE+Tudca: Positive appraisal without composition measurements; unspecified PCT identity not inferred. Proposed Cardarine swap is not a completed outcome.

Stacks

LGD with RAD or ostarine	Both dual-SARM combinations recur, with competing claims about strength and muscle retention. Reports do not establish better outcomes from adding a second SARM.
Cardarine or MK-677	Cardarine appears for endurance/cutting; MK-677 for appetite, sleep and recovery. Triple combinations and fixed blends also appear, with poor control over individual effects.
Other additions	Older menus include S-4 with LGD and niche YK-11 pairings. Testosterone-base use is disputed; fish oil, NAC and TUDCA discussions do not establish protection.

Notes

LGD + RAD-140: Community descriptions pair LGD fullness with a drier or stronger appearance attributed to RAD. Charts include LGD ~5–10 mg plus RAD ~10–20 mg for ~6–8 weeks. These do not establish added benefit, a reliable appearance change or a ranked adverse-effect burden. [community]

LGD + ostarine (MK-2866): Forums assign different muscle-retention or appearance roles to the partners. Calling ostarine gentler or beginner-suitable does not establish comparative safety or a reason to combine androgen-receptor drugs. [community]

More compounds do not settle the argument. Receptor-competition and synergy explanations conflict in LGD/ostarine threads. An AnabolicMinds discussion contrasts brain fog and poor tolerability with another member’s no-side-effect experience; one disclosed a vendor-representative relationship. These accounts do not prove superior multi-agent results. Stacking LGD-4033 with Ostarine. Useless stack? (Community discussion · Accessed 2026-09-30) · LGD and MK-677 stack. Does this look ok? (Community discussion · Accessed 2026-09-30)

LGD + Cardarine (GW-501516): Discussed for strength plus endurance or cutting goals. Cardarine is not a SARM; its chronic rodent studies found tumors across tested active amounts. Those studies do not establish the long-term safety of human combinations. [community] [animal]

LGD + MK-677 (Ibutamoren): Extremely common “size + sleep/appetite” bulk stack; Cardaci 2022 is the main published human co-admin case (LBM and fat both up; lipids/liver/hormones worsened on-cycle). Hunger can sabotage recomp deficits. [trial] [community]

LGD + RAD + Cardarine: Appears in recomp or cutting templates. Multiple simultaneous agents make attribution difficult, but the reports do not quantify a maximum risk or demonstrate superior results. [community]

LGD + RAD + MK-677, sometimes Cardarine: Multi-agent bulk accounts receive both enthusiastic and critical replies. Simultaneous changes make it difficult to identify which compound contributed to benefits or adverse effects. [community]

Older combinations and monitoring talk remain relevant. Older menus include S-4 50 mg with LGD 10 mg, LGD with RAD and MK-677, and niche YK-11 pairings. Posters discuss pre-, mid- (week 3–5), end- and post-treatment tests: testosterone, LH/FSH, SHBG, estradiol, lipids and liver enzymes, sometimes glucose. Fish oil, NAC or TUDCA talk does not prove protection.

Test-base debate: Advanced forums argue real testosterone (TRT/blast) as a base instead of multi-SARM-only; others stay oral-only for needle aversion — cultural split, not medical guidance. [community]

Source context — LGD and MK-677 stack. Does this look ok?: Disagreement with extensive co-drug use; commercial relationship disclosed by one participant. Page 2 not inspected; vendor authenticity accusations and injectable tangents not carried into oral stack article.

Watch for

Suppression and lipids	One self-reported LGD/MK-677 log paired strength gains with testosterone falling from 576 to 112 ng/dL and HDL from 49 to 28 mg/dL. Feeling good did not mean reassuring values.
Partner-specific problems	Saved reports include MK-677 hunger, water and glucose concerns; S-4 yellow tint/night-vision problems; and acne, shedding, nausea, sleep or mood changes.
Serious harm	Saved FDA warnings include liver, cardiovascular, sexual and reproductive harms. Yellowing skin/eyes, dark urine or itching need clinical assessment; Cardarine's preclinical toxicity does not define a safe human dose.
Identity and tested sport	A historical product survey found frequent label/content mismatch. The 2026 WADA list prohibits the named stack agents at all times; half-life is not a detection window.

Notes

Partners bring their own cautions. The older record includes MK-677 hunger, water and glucose concerns; S-4 yellow-tinted or impaired night vision; headache, acne, hair shedding, nausea and sleep or mood changes. Masculinization concerns in women are poorly characterized. More agents make the cause harder to identify.

Exit discussions include visible warning symptoms. Original exit discussions mention yellowing skin or eyes, dark urine and itching; these need clinical assessment rather than another stack adjustment.

Unapproved products can cause serious harm. FDA warns about liver injury, cardiovascular risks, sexual dysfunction and reproductive harms with SARMs. WADA’s Cardarine alert reports termination after serious preclinical toxicity; animal cancer concerns do not define a safe human dose. FDA warns about SARMs among teens and young adults (Official context · Accessed 2026-09-30) · WADA alert on GW501516 (Official context · Accessed 2026-09-30) · Preserved Cardarine animal cancer context (Animal context · Accessed 2026-09-30)

Label amounts are not verified contents. A 44-product laboratory survey found SARMs in 52%, other unapproved drugs in 39%, unlabeled substances in 25%, no active drug in 9%, and label-matching amounts in 41%. This historical sample does not certify today’s products. Van Wagoner et al. — chemical composition of marketed SARMs (Official context · Accessed 2026-09-30)

Tested sport has separate consequences. The 2026 WADA list prohibits LGD, RAD, ostarine, S-4, MK-677 and Cardarine at all times. Half-life talk is not a drug-test clearance window. 2026 WADA Prohibited List (Official context · Accessed 2026-09-30)

Source context — FDA warns about SARMs among teens and young adults: Class-level warning, not a dose-specific incidence estimate or a head-to-head stack trial.

Source context — WADA alert on GW501516: Alert not a clinical cancer-risk estimate; linked toxicology abstracts not inspected.

Source context — Preserved Cardarine animal cancer context: Underlying rodent abstracts were not inspected this turn; original ~3 mg/kg dose omitted from fresh article because it cannot define human safety.

Source context — Van Wagoner et al. — chemical composition of marketed SARMs: 2016 purchases reported in 2017, not a representative 2026 market audit or a study of users. Abstract only.

Source context — 2026 WADA Prohibited List: Sport rule, not medical safety or detection-duration evidence.

Full notes

Ligandrol recomp stacks are combinations built around LGD-4033 for losing fat while keeping or gaining muscle. The partners and products vary, so this is a family of forum plans, not one compound or proven protocol. Accounts include strength and fullness, little extra benefit, and adverse effects.

What this stack name means

LGD is the anchor; the partners change. LGD-4033, also called Ligandrol, is an oral SARM: a drug that acts at androgen receptors. RAD-140, ostarine and S-4 are other SARMs. Cardarine is a different metabolic drug; MK-677 stimulates growth-hormone release. Calling them all SARMs hides different effects and risks. Community
Oral liquids, capsules and fixed blends. These discussions concern whole-body exposure, not a local repair peptide. Separate bottles and premixed products appear; a blend prevents adjusting one ingredient independently. A label’s combined milligrams do not identify each component’s amount. Community

What people hope to get

Hold muscle while losing fat. Recomp means getting leaner while retaining or gaining muscle. Posters assign LGD fullness and strength, RAD a drier look, ostarine muscle retention or joint comfort, and Cardarine easier cardio. These are community expectations, not demonstrated stack rankings. Community Reddit r/sarmssourcetalk
More training capacity, sometimes more appetite. MK-677 is added for sleep, hunger and recovery feel. Hunger can help a bulk but undermine a calorie deficit. A better workout or fuller appearance does not establish fat loss or new muscle. Community Reddit r/sarmssourcetalk

Doses people discuss

Reported amounts describe discussion, not instructions. mg means milligrams; mg/mL describes liquid concentration. Unspecified forms or frequencies stay unspecified.

LGD component: 2.5–5, 5–10, or 10–15+ mg/day. These separate oral bands occur in the older community record, not safety tiers. Partner charts list RAD 5–10, 10–20 or 20–30 mg/day; ostarine 10–25 mg/day, sometimes 30; Cardarine 10–20; MK-677 10–25. Each amount belongs to that drug, not the entire stack. Community
Actual LGD/ostarine reports differ. One user reported 10 mg of each every morning. Another described LGD 10 mg with ostarine 15 mg for four weeks, then 15 mg with 22.5 mg for six weeks; daily frequency is implicit in the cycle account, not explicitly stated. Reddit r/sarmssourcetalk
A proposed three-agent cycle is not an outcome. A daily plan listed LGD 20 mg for eight weeks, ostarine 25 mg and Cardarine 10 mg for seven. Replies challenged it; the author agreed to reduce LGD and omit ostarine. No completed results were posted there. Reddit r/sarmssourcetalk
Liquid blend: 20, 25 and 20 mg per mL. A T Nation poster described LGD, ostarine and MK-677 in that order, totaling 65 mg/mL. That is labeled concentration, not the amount swallowed each day; the thread does not establish blend contents or a completed stack result. T Nation Pharma forum

Half-life

LGD’s repeated figure is 24–36 hours. A Reddit timing debate explicitly links this number to the low-dose LGD-only human trial through More Plates More Dates. It is trial-derived information repeated by users, not a community measurement of a stack. Reddit r/sarmssourcetalk
There is no single stack half-life. Partners have separate kinetics. Older summaries repeat about 24 hours for ostarine and describe once-daily or split Cardarine and nighttime MK-677. Timing habits are not measured clearance. Feeling residual effects for weeks cannot establish a longer drug half-life. Community Reddit r/sarmssourcetalk

Onset: when changes appear

Early feelings and later physique changes differ. Older accounts place fullness in days 1–7 and training changes in weeks 1–2. An LGD/ostarine user described malaise for the first three days; another reported little soreness nearly a month in. These are different endpoints, not one onset clock. Community Reddit r/sarmssourcetalk
An adjunct can be felt much sooner. In a cutting discussion, a commenter described intense hunger roughly two hours after 12.5 mg MK-677. That was an MK response, not onset of the planned LGD blend’s recomp effect. Reddit r/sarmssourcetalk

Duration: how long changes last

Single-dose benefit duration is unknown. Daily-use logs describe weeks of training and appearance changes. They do not show how long one dose improves performance. A 2026 LGD/MK-677 author expected weight loss after stopping but had not measured retained muscle at that point. Personal report
Feeling recovered does not establish recovery. The same author later reported good energy and strength 23 days into post-cycle treatment, while saying repeat testosterone testing had not happened. Persistent benefit, normal hormones and drug clearance are separate questions. Personal report

Cycles and time off

Six to eight weeks is an older chart pattern. The record also contains 4–6, 8–10 and 8–12-week plans. A newer pill-stack author reported three months on and five months off; that is one account, not a safe alternative calendar. Community Personal report
Post-cycle treatment is contested. Older charts discuss tamoxifen 10–20 mg/day for about four weeks, or clomiphene-based blocks of 3–6 weeks. Starts range from the next day to days or 1–2 weeks later; minority on-cycle SERM use also appears. None establishes a validated recovery schedule. Community
Break rules do not prove readiness. Equal-or-longer time off, sometimes plus treatment time, is a forum heuristic. Solo-first versus stack-first and adding a testosterone base remain disagreements; extra drugs complicate attribution and recovery. Community Community

Hormones, adverse effects and product uncertainty

Feeling good can coexist with concerning values. A July 2026 LGD/MK-677 log reported strength gains but testosterone falling from 576 to 112 ng/dL and HDL from 49 to 28 mg/dL. These are self-reported numbers, not independently verified labs; mood and swelling also changed. Personal report
Partners bring their own cautions. The older record includes MK-677 hunger, water and glucose concerns; S-4 yellow-tinted or impaired night vision; headache, acne, hair shedding, nausea and sleep or mood changes. Masculinization concerns in women are poorly characterized. More agents make the cause harder to identify. Community
Exit discussions include visible warning symptoms. Original exit discussions mention yellowing skin or eyes, dark urine and itching; these need clinical assessment rather than another stack adjustment. Community
Unapproved products can cause serious harm. FDA warns about liver injury, cardiovascular risks, sexual dysfunction and reproductive harms with SARMs. WADA’s Cardarine alert reports termination after serious preclinical toxicity; animal cancer concerns do not define a safe human dose. Official context Official context Animal context
Label amounts are not verified contents. A 44-product laboratory survey found SARMs in 52%, other unapproved drugs in 39%, unlabeled substances in 25%, no active drug in 9%, and label-matching amounts in 41%. This historical sample does not certify today’s products. Official context
Tested sport has separate consequences. The 2026 WADA list prohibits LGD, RAD, ostarine, S-4, MK-677 and Cardarine at all times. Half-life talk is not a drug-test clearance window. Official context

From community discussion

Less soreness, mostly water, or no extra benefit. LGD/ostarine reports include less soreness and better definition alongside mostly water-weight gain and some fat gain. A different user said the combination produced fewer gains than LGD alone and more suppression. Joint comfort is not proof of tissue healing. Reddit r/sarmssourcetalk Reddit r/sarmssourcetalk
Sexual side effects can emerge mid-cycle. Another commenter reported erectile dysfunction three to four weeks into testosterone, LGD and RAD co-use. Their explanation involving lipids was speculation. Their subsequent medication use does not establish a treatment for other users. Reddit r/sarmssourcetalk
Hunger and bloat can derail the cut. Cutting-thread replies disagree about how much water LGD brings. The original poster said MK-677 had not bloated them; others described intense hunger. Cardarine’s proposed fat-burning role was disputed even within that thread. Reddit r/sarmssourcetalk
More compounds do not settle the argument. Receptor-competition and synergy explanations conflict in LGD/ostarine threads. An AnabolicMinds discussion contrasts brain fog and poor tolerability with another member’s no-side-effect experience; one disclosed a vendor-representative relationship. These accounts do not prove superior multi-agent results. Reddit r/sarmssourcetalk AnabolicMinds forum
Older combinations and monitoring talk remain relevant. Older menus include S-4 50 mg with LGD 10 mg, LGD with RAD and MK-677, and niche YK-11 pairings. Posters discuss pre-, mid- (week 3–5), end- and post-treatment tests: testosterone, LH/FSH, SHBG, estradiol, lipids and liver enzymes, sometimes glucose. Fish oil, NAC or TUDCA talk does not prove protection. Community Community Community

What measured research can tell us

LGD alone is not a recreational stack. In 76 healthy men, 0.1, 0.3 or 1 mg/day for 21 days produced a 24–36-hour elimination half-life and roughly threefold day-21 accumulation. Lean mass increased; fat mass did not significantly change. Testosterone and HDL fell. Short low-dose recovery cannot validate higher-dose combinations. Official context
The published LGD/MK-677 case was not successful recomp proof. One man took oral LGD 10 mg and MK-677 15 mg daily for five weeks. Lean mass rose 3.1%, but fat mass rose 15.4%; testosterone, lipids, liver enzymes and bone measures worsened. Four-week follow-up did not normalize every measure. One case cannot isolate either drug. Official context